Comparison of cefotetan and cefoxitin as prophylaxis in cesarean section. 1986

M W Varner, and C P Weiner, and C R Petzold, and R P Galask

A study comparing the efficacy of cefotetan versus cefoxitin for prophylaxis in patients undergoing cesarean section was carried out at the University of Iowa. After institutional review, 36 subjects who met the study criteria and agreed to participate were entered into the study; of these, 29 were evaluable for efficacy. Twenty subjects received a single 2 gm dose of cefotetan, and nine subjects received three 2 gm doses each of cefoxitin. Both antibiotics were administered intravenously at the time the umbilical cord was clamped. The subsequent doses of cefoxitin were given intravenously at four and eight hours after the initial dose. Clinical and bacteriologic responses were evaluated; there were no statistically significant differences between the two groups, and both antibiotics provided effective prophylaxis against infection. It appears that cefotetan is a satisfactory antibiotic choice for cesarean section prophylaxis. Further, in this small study it appears that a single dose of cefotetan is as effective as three doses of cefoxitin. This implies that cefotetan would not only decrease administration time and supplies but would decrease the cost to the patient while maintaining very acceptable infection rates.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011292 Premedication Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION. Premedications
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002440 Cefoxitin A semisynthetic cephamycin antibiotic resistant to beta-lactamase. Cefoxitin Sodium,MK-306,Mefoxin,Mefoxitin,Méfoxin,MK 306,MK306,Sodium, Cefoxitin
D002513 Cephamycins Naturally occurring family of beta-lactam cephalosporin-type antibiotics having a 7-methoxy group and possessing marked resistance to the action of beta-lactamases from gram-positive and gram-negative organisms. Antibiotics, Cephamycin,Cephamycin,Cephamycin Antibiotics
D002585 Cesarean Section Extraction of the FETUS by means of abdominal HYSTEROTOMY. Abdominal Delivery,Delivery, Abdominal,C-Section (OB),Caesarean Section,Postcesarean Section,Abdominal Deliveries,C Section (OB),C-Sections (OB),Caesarean Sections,Cesarean Sections,Deliveries, Abdominal
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug

Related Publications

M W Varner, and C P Weiner, and C R Petzold, and R P Galask
April 1986, American journal of obstetrics and gynecology,
M W Varner, and C P Weiner, and C R Petzold, and R P Galask
April 1986, American journal of obstetrics and gynecology,
M W Varner, and C P Weiner, and C R Petzold, and R P Galask
April 1981, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
M W Varner, and C P Weiner, and C R Petzold, and R P Galask
July 1989, Journal of chemotherapy (Florence, Italy),
M W Varner, and C P Weiner, and C R Petzold, and R P Galask
December 1987, The Journal of reproductive medicine,
M W Varner, and C P Weiner, and C R Petzold, and R P Galask
July 1992, American journal of obstetrics and gynecology,
M W Varner, and C P Weiner, and C R Petzold, and R P Galask
January 1997, Akusherstvo i ginekologiia,
M W Varner, and C P Weiner, and C R Petzold, and R P Galask
July 1989, Journal of chemotherapy (Florence, Italy),
M W Varner, and C P Weiner, and C R Petzold, and R P Galask
June 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!